

Quarterly Report for the Period Ended 31 March 2019

Highlights

- **Licensing Term Sheet signed for fourth generation Olay Magnetic Infuser as P&G expands rollout**
- **New OBJ technologies showcased at CES the world's largest tech & innovation expo**

Financials

OBJ Limited banked cash receipts from customers of \$488,226 during the quarter.

In addition, the Company received its R&D tax rebate of \$758,069 during the period.

The Company's cash balance at the end of the period was approximately \$3m.

Corporate

During the quarter, OBJ executed a new Licensing Term Sheet with Procter & Gamble (P&G) for the fourth generation of the Olay Magnetic Infuser.

The new Magnetic Infuser, which incorporates OBJ's newest multi-active technology, will continue the expansion of Olay's highly successful Magnemask product initiative after it was launched across Asia, the USA and Australia during 2017 and 2018. The new Infuser is expected to move quickly into production with the exact launch date to be confirmed.

Olay's Magnemask provides highly targeted and individual skincare treatments when used in conjunction with Olay's Sheet Mask and Jar Mask formulations.

Since the launch of the first OBJ licensed product in October 2014, by P&G's prestigious skincare brand SK-II, P&G and OBJ have worked closely together in the field of device amplified chemistry.

As announced in January, OBJ's Personalisation technology, developed in conjunction with P&G as part of the second technology platform, was showcased at the 2019 International Consumer Electronics Show (CES) in Las Vegas, USA.

OBJ's In-Field Programmable Array Technology was licensed to P&G in early 2018. Developed in conjunction with the Olay brand, the system combines smartphone skin analysis software and new wand tracking technology to determine the optimum skincare treatment for an individual. The system instructs an applicator to deliver highly

Directors

Mr Antonio Varano
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Cameron Reynolds
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered

Office:
284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
www.obj.com.au
ABN: 72 056 482 636

personalised skincare treatments to the precise needs of individual users. The Olay Wand and smartphone interface were developed as part of OBJ's technology partnership with the world's largest consumer products company.

CES was held on 9-12 January 2019 and is the world's largest consumer electronics trade show. In 2018, almost 200,000 industry and media professionals attended, generating 71.7 billion media impressions worldwide.



Outlook

During the period, OBJ appointed John Poynton of Jindalee Partners as corporate advisor to the Company.

OBJ's board and management continues to advance negotiations with P&G pertaining to its overarching product development agreement as well as new and existing work plans for its technologies. The Company expects to provide updates on this and other operational and corporate activities in the near term.

ABOUT OBJ

Directors

Mr Antonio Varano
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Cameron Reynolds
Dr Chris Quirk

Company Secretary

Mr John Palermo

OBJ develops proprietary magnetic microarray drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

ABOUT OBJ'S TECHNOLOGIES

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost microarray film technology that utilises diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's

Registered

Office:

284 Oxford Street
Leederville

Western Australia 6007

Tel: +61 8 9443 3011

www.obj.com.au

ABN: 72 056 482 636

30 April 2019

Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

FORWARD-LOOKING STATEMENTS

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward-looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

For more information:

Matthew Wright

matt@nwrcommunications.com.au

Phone: +61 451 896 420

Directors

Mr Antonio Varano
Mr Steven Schapera
Mr Jeffrey Edwards
Mr Cameron Reynolds
Dr Chris Quirk

Company Secretary

Mr John Palermo

Registered

Office:

284 Oxford Street
Leederville
Western Australia 6007
Tel: +61 8 9443 3011
www.obj.com.au
ABN: 72 056 482 636